5-溴苯并呋喃-2-羧酸 | 10242-11-2

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 5-溴苯并呋喃-2-羧酸
• 中文别名: 5-溴-苯并呋喃-2-酸；5-溴-1-苯并呋喃-2-羧酸
• 英文名称: 5-bromobenzo[b]furan-2-carboxylic acid
• 英文别名: 5-bromobenzofuran-2-carboxylic acid；5-bromo-1-benzofuran-2-carboxylic acid
• CAS: 10242-11-2
• 化学式: C₉H₅BrO₃
• mdl: MFCD00093973
• 分子量: 241.041
• InChiKey: QKUWZCOVKRUXKX-UHFFFAOYSA-N

物化性质

• 熔点：
  257 °C
• 沸点：
  370.9±22.0 °C(Predicted)
• 密度：
  1.784±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Name:	5-Bromobenzo[b]furan-2-carboxylic acid Material Safety Data Sheet
Synonym:
CAS:	10242-11-2

Section 1 - Chemical Product MSDS Name:5-Bromobenzo[b]furan-2-carboxylic acid Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
10242-11-2	5-Bromobenzo[b]furan-2-carboxylic acid	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 10242-11-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 253 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H5BrO3
Molecular Weight: 241.04

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases, amines, reducing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 10242-11-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Bromobenzo[b]furan-2-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 10242-11-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 10242-11-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 10242-11-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴苯并呋喃-2-羧酸 在 氯化亚砜 、 氨 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 25.0~140.0 ℃ 、300.01 kPa 条件下， 反应 22.5h， 生成 维拉佐酮
  参考文献：
  名称：

  维拉佐酮的合成研究

  摘要：

  以 4-氰基苯胺和 5-溴-2-羟基苯甲醛为起始原料，描述了一种合成维拉佐酮的新途径，总产率为 24%，纯度为 99%。首先，通过 4-氰基苯胺的重氮化合成中间体 (3-(4-氯丁基)-1H-indole-5-carbonitrile)，然后用 6-氯己醛进行 Fischer 吲哚环化。随后，通过用哌嗪对 5-溴苯并呋喃-2-甲酰胺进行芳香族亲核取代，生成另一种中间体 5-(哌嗪-1-基) 苯并呋喃-2-甲酰胺。最后，通过用 Et3N/K2CO3 处理上述两个关键中间体的亲核取代获得维拉佐酮。与原始工艺相比，该路线避免了使用昂贵且有毒的试剂，并解决了安全、环境问题和高成本等问题。

  DOI：

  10.1177/1747519819893293
• 作为产物：
  描述：

  2-乙酰基-5-溴苯并[b]呋喃 以77%的产率得到5-溴苯并呋喃-2-羧酸
  参考文献：
  名称：

  Structure-In Vitro Activity Relationships of Pentamidine Analogues and Dication-Substituted Bis-Benzimidazoles as New Antifungal Agents

  摘要：

  摘要：对于20种戊二胺类似物、7种戊二胺的主要代谢产物以及30种二阳离子取代的双苯并咪唑类化合物进行了筛选，评估它们对念珠菌和隐球菌的抑制和杀真菌活性。大多数化合物的MIC（80%菌株被抑制的最小抑菌浓度）与两性霉素B和氟康唑相当。与氟康唑不同，许多这些化合物表现出强效的杀真菌活性。对于念珠菌而言，最有效的化合物的MIC80为≤0.09μg/ml，对于隐球菌而言，最有效的化合物的MIC80为0.19μg/ml。选择的化合物也对曲霉、索兰镰孢霉、除念珠菌外的其他种类的念珠菌，以及氟康唑耐药菌株的活性。从这里呈现的数据清楚地表明，有必要进行进一步的研究，以确定这些化合物的结构活性关系、作用机制和毒性，以及它们在体内的疗效，以确定它们的临床潜力。

  DOI：

  10.1128/aac.42.10.2495

文献信息

• [DE] 2-HETEROARYLCARBONSÄUREAMIDE<br/>[EN] 2-HETEROARYL CARBOXAMIDES<br/>[FR] 2-HETEROARYLCARBOXAMIDES
  申请人：BAYER HEALTHCARE AG

  公开号：WO2003104227A1

  公开（公告）日：2003-12-18

  Die Erfindung betrifft neue 2-Heteroarylcarbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten und zur Verbesserung der Wahrnehmung, Konzentrationsleistung, Lernleistung und/oder Gedächtnisleistung. (I): in welcher R1 1-Aza-bicyclo [2.2.2]oct-3-yl, welches gegebenenfalls über das Sticktoffätom mit einem Rest ausgewählt aus der Gruppe C1-C4-Alkyl, Benzyl und Oxy substituiert ist, A Sauerstoff oder Schwefel, der Ring B Benzo oder Pyrido, die jeweils gegebenenfalls durch Reste aus der Reihe Halogen, Cyano, Formyl, Trifluormethyl, Trifluormethoxy, Nitro, Amino, C1-C6-Alkyl und C1-C6-Alkoxy substituiert sind, E C≡C, Aryl und Heteroaryl, wobei Aryl und Heteroaryl durch Reste aus der Reihe Halogen, Cyano, Trifluormethyl, Trifluormethyl, Trifluormethoxy, Nitro, Amino, C1-C6-Alkoxy und C1-C6-Alkyl substituiert sein Können, bedeuten, sowie die Solvate, Salze oder Solvate der Salze dieser Verbindungen.

  这项发明涉及新的2-杂环芳基羧酰胺及其用于制备用于治疗和/或预防疾病以及改善感知、注意力、学习和/或记忆能力的药物的用途。其中，R1为1-Aza-bicyclo[2.2.2]oct-3-yl，可能通过氮原子与来自C1-C4-烷基、苄基和氧的基团中的一种取代，A为氧或硫，环B为苯并或吡啶，并且可以通过来自卤素、氰基、甲酰基、三氟甲基、三氟甲氧基、硝基、氨基、C1-C6-烷基和C1-C6-烷氧基的基团取代，E为C≡C、芳基和杂环芳基，其中芳基和杂环芳基可以通过来自卤素、氰基、三氟甲基、三氟甲基、三氟甲氧基、硝基、氨基、C1-C6-烷氧基和C1-C6-烷基的基团取代，以及这些化合物的溶剂化合物、盐或盐的溶剂化合物。
• Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
  作者：Duncan A. Hay、Oleg Fedorov、Sarah Martin、Dean C. Singleton、Cynthia Tallant、Christopher Wells、Sarah Picaud、Martin Philpott、Octovia P. Monteiro、Catherine M. Rogers、Stuart J. Conway、Timothy P. C. Rooney、Anthony Tumber、Clarence Yapp、Panagis Filippakopoulos、Mark E. Bunnage、Susanne Müller、Stefan Knapp、Christopher J. Schofield、Paul E. Brennan

  DOI：10.1021/ja412434f

  日期：2014.7.2

  compound bound to the CREB binding protein (CBP) and the first bromodomain of BRD4 (BRD4(1)) were used to guide the design of more selective compounds. The crystal structures obtained revealed two distinct binding modes. By varying the aryl substitution pattern and developing conformationally constrained analogues, selectivity for CBP over BRD4(1) was increased. The optimized compound is highly potent (Kd

  缺乏针对溴结构域和末端外 (BET) 亚家族之外的溴结构域的小分子抑制剂。在这里，我们描述了人类赖氨酸乙酰转移酶 CBP/p300 溴结构域模块的高效和选择性配体，由一系列 5-异恶唑基苯并咪唑开发而成。我们的出发点是片段命中，使用 Suzuki 偶联、苯并咪唑形成反应和还原胺化的平行合成将其优化为更有效和选择性更强的先导化合物。使用热稳定性测定法研究了先导化合物对其他溴结构域家族成员的选择性，结果显示对结构相关的 BET 家族成员有一些抑制作用。为了解决 BET 选择性问题，与 CREB ​​结合蛋白 (CBP) 和 BRD4 的第一个溴结构域 (BRD4(1)) 结合的先导化合物的 X 射线晶体结构用于指导更具选择性的化合物的设计。获得的晶体结构揭示了两种不同的结合模式。通过改变芳基取代模式和开发构象受限的类似物，增加了 CBP 超过 BRD4(1) 的选择性。优化后的化合物具有高效 (Kd
• FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF
  申请人：Guangzhou Henovcom Bioscience Co. Ltd.

  公开号：EP3401315A1

  公开（公告）日：2018-11-14

  The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.

  本公开揭示了一种FXR受体调节剂及其制备和使用，涉及药物化学技术领域。本公开提供了一种具有结构式I或其药用可接受盐、立体异构体、溶剂合物或前药的FXR受体调节剂，可与FXR受体（即NR1H4）结合，并作为FXR激动剂或部分激动剂用于预防和治疗由FXR介导的疾病，如慢性肝内或肝外胆汁淤积、慢性胆汁淤积或急性肝内胆汁淤积引起的肝纤维化、慢性乙型肝炎、胆结石、肝癌、结肠癌或肠道炎症性疾病等。具体而言，对于某些化合物，它们的FXR激动剂活性的EC50值低于100nM，表现出优异的FXR激动剂活性，并有望为由FXR介导的疾病在临床治疗中提供新的药物选择。
• Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site
  作者：Yu-Ying Shao、Yong Yin、Bao-Ping Lian、Jia-Fu Leng、Yuan-Zheng Xia、Ling-Yi Kong

  DOI：10.1016/j.ejmech.2020.112105

  日期：2020.3

  with the IC50 value of 0.18 μM against HT29 cells, which was significantly better than that of the reference drugs shikonin and CA-4. What's more, 6c could inhibit tubulin polymerization and compete with [3H] colchicine in binding to tubulin. Further biological studies depicted that 6c can induce cell apoptosis and cell mitochondria depolarize, regulate the expression of apoptosis related proteins in

  设计并合成了一系列新的紫草素-苯并[b]呋喃衍生物作为微管蛋白聚合抑制剂，并对其生物学活性进行了评估。大多数化合物显示出与紫草素相当的抗癌细胞增殖活性，同时对非癌细胞具有较低的细胞毒性。其中，化合物6c对HT29细胞显示出强大的抗癌活性，IC50值为0.18μM，显着优于参考药物紫草素和CA-4。而且，6c可以抑制微管蛋白聚合，并与[3H]秋水仙碱竞争与微管蛋白的结合。进一步的生物学研究表明6c可以诱导细胞凋亡并使细胞线粒体去极化，调节HT29细胞中凋亡相关蛋白的表达。除了，6c激活了HT29细胞在G2 / M期的细胞周期停滞，并影响了细胞周期相关蛋白的表达。此外，6c显示出对细胞迁移和管形成的有效抑制，这有助于抗血管生成。这些结果促使我们将6c视为潜在的微管蛋白聚合抑制剂，值得进一步研究。
• Catalytic Asymmetric Dearomatization by Visible‐Light‐Activated [2+2] Photocycloaddition
  作者：Naifu Hu、Hoimin Jung、Yu Zheng、Juhyeong Lee、Lilu Zhang、Zakir Ullah、Xiulan Xie、Klaus Harms、Mu‐Hyun Baik、Eric Meggers

  DOI：10.1002/anie.201802891

  日期：2018.5.22

  the catalytic asymmetric dearomatization by visible‐light‐activated [2+2] photocycloaddition with benzofurans and one example of a benzothiophene is reported, thereby providing chiral tricyclic structures with up to four stereocenters including quaternary stereocenters. The benzofurans and the benzothiophene are functionalized at the 2‐position with a chelating N‐acylpyrazole moiety which permits the

  报道了一种通过可见光活化的[2 + 2]光环加成与苯并呋喃和一个苯并噻吩实例进行催化不对称脱芳香化反应的新方法，从而提供了具有四个立体中心（包括四级立体中心）的手性三环结构。苯并呋喃和苯并噻吩在2位被N-酰基吡唑螯合部分官能化，从而允许可见光活化的手性铑路易斯手性酸催化剂的配位。计算分子模型揭示了异常区域选择性的起源，并确定了杂环中的杂原子是区域控制的关键。